20-224 - Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19Status: open
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19
Treatment to help fight infection such as COVID-19
This study will help to understand whether patients with COVID-19 disease benefit from acalabrutinib, a drug approved for treatment of some types of blood cancer, and if it appears to be safe to use in the disease. Acalabrutinib alters the body’s immune system, which helps fight virus infections, and may improve the way the immune system fights COVID-19 disease. Subjects participating in this study will be randomly assigned to receive either best supportive care with acalabrutinib or best supportive care without acalabrutinib.